Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes

Figures & data

Table 1 Prevalence of different CNV sub-types at baseline

CNV sub-type	Eyes (n)	Eyes (%)
Predominantly classic	13	17
Minimally classic	20	26
Occult	43	57

Abbreviation: CNV, choroidal neovascularization.

Figure 1 Influence of baseline VA on visual outcomes.

Notes: Mean change in VA from baseline over a 36-month period, stratified by baseline VA. Linear regression analysis was used to determine the relationship between visual outcomes and baseline VA. P-values at each 12-monthly time interval: 0.092 (12 months), <0.001 (24 months), and <0.001 (36 months). A correlation coefficient (R) of 0.414 at 3 years suggests a positive correlation.
Abbreviations: VA, visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study.

Table 2 Visual outcomes at 36 months, stratified by baseline VA

Baseline VA (ETDRS letters)	Eyes (n)	Mean VA (ETDRS letters)	Mean VA gain (ETDRS letters)	Eyes gaining ≥15 ETDRS letters (%)
≤35	30	46	12.4	49
36–54	26	44	0.4	29
≥55	20	59	0.2	0

Abbreviations: VA, visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study.

Figure 2 Influence of injection frequency on visual outcomes.

Notes: Mean change in VA from baseline over a 36-month period, stratified by injection frequency. Linear regression analysis was used to determine the relationship between visual outcomes and injection frequency. P-values at each 12-monthly time interval: 0.011 (12 months), 0.007 (24 months), and 0.036 (36 months). A correlation coefficient (R) of 0.244 at 3 years suggests a positive correlation.
Abbreviations: VA, visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study.